HilleVax Q1 net loss widens to $46.8M; cash at $272.7M; NEST-IN1 data due mid-2024

HilleVax, Inc.

2024-Q3 EPS reported -$0.97

Net loss $46.8M vs $26.9M YoY; R&D expenses $26.0M (up from $23.2M); G&A $8.5M (up from $5.8M).
Cash, equivalents and marketable securities $272.7M as of March 31, 2024, down from $303.5M at Dec 31, 2023.
Topline safety and efficacy data from NEST-IN1 Phase 2b trial of HIL-214 in infants expected in mid-2024.
Appointed Sean McLoughlin as COO during Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HilleVax, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter 2024 was $46.8 million, compared to $26.9 million for the first quarter 2023.

Period: the quarter ended March 31, 2024
Net income: Net loss for the first quarter 2024 was $46.8 million, compared to $26.9 million for the first quarter 2023
Result: reported results

Exact text from the filing

HilleVax, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-056949

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.